CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee March 29 voted 17-6 that all obesity drugs should be vetted for cardiovascular risk, but some could rely on a meta-analysis rather than an outcomes trial.
You may also be interested in...
‘Weight Management’ Guidance Changes From FDA Could Tip Scales In Obesity Reimbursement Debate
Expected revision to the 2007 draft might more clearly communicate that obesity is a disease than the earlier guidance, and could provide advice on getting indications for treating complications. If US FDA embraces the new thinking, it could help build the case for Medicare reimbursement.
Orexigen Sheds LIGHT On Potential CV Benefit For Contrave
The biotech disclosed in an SEC filing that its obesity drug may actually provide a cardiovascular benefit to patients based on early results from an ongoing outcomes study.
Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.